News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Daily News Quadruple Therapy Costs Prohibitive for Many HFrEF Patients L.A. McKeown June 21, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Daily News Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis Caitlin E. Cox May 03, 2022
News Daily News Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries Todd Neale April 20, 2022
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Features When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles Todd Neale September 28, 2021
News Daily News HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds Michael O'Riordan August 13, 2020
News Features Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses Shelley Wood December 23, 2019
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Daily News Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway Michael O'Riordan January 02, 2018
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017